Selective 5-hydroxytryptamine 2c receptor agonists derived from the lead compound tranylcypromine: Identification of drugs with antidepressant-like action

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1885-1902

  Sung, Jin Cho ^a   Jensen, Niels H ^b   Kurome, Toru ^a   Kadari, Sudhakar ^a   Manzano, Michael L ^c   Malberg, Jessica E ^c   Caldarone, Barbara ^c   Roth, Bryan L ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PSYCHOGENICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 NAPHTHALEN 2 YLCYCLOPROPYL)METHYLAMINE; (2 PHENYLCYCLOPROPYL)METHYLAMINE; 1 AMINOMETHYL 2 PHENYLCYCLOPROPANE DERIVATIVE; 2 PHENYLCYCLOPROPANECARBOXYLIC ACID; 2 PHENYLCYCLOPROPANECARBOXYLIC ACID AMIDE; 2 PHENYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER; 2 PHENYLCYCLOPROPYL)METHYLAMINE; [2 (2 BROMOPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (2 CHLOROPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (2 FLUOROPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (2 HYDROXYPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (2 METHYLPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (2 TRIFLUOROMETHYLPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (3 CHLOROPHENYL)CYCLOPROPYL]METHYLAMINE; [2 (3 FLUOROPHENYL)CYCLOPROPYL]METHYLAMINE; CARBOXYLIC ACID DERIVATIVE; CYCLOPROPANE DERIVATIVE; ESTER DERIVATIVE; ISOINDOLE DERIVATIVE; METHYLAMMONIUM; N BENZYL (2 PHENYLCYCLOPROPYL)AMINE; N BENZYL (2 PHENYLCYCLOPROPYLMETHYL)AMINE; N ISOPROPYL (2 PHENYLCYCLOPROPYL)AMINE; N METHYL (2 PHENYLCYCLOPROPYL)AMINE; N METHYL (2 PHENYLCYCLOPROPYLMETHYL)AMINE; N,N DIMETHYL (2 PHENYLCYCLOPROPYL)AMINE; PYRAZINOISOINDOLINE; SEROTONIN 2C AGONIST; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM; CELL LINE; CYCLOPROPANES; HUMANS; MALE; METHYLAMINES; MICE; MICE, INBRED BALB C; MONOAMINE OXIDASE INHIBITORS; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2C; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANYLCYPROMINE;

EID: 64549119709     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801354e     Document Type: Article

References (55)

1. Hoyer, D.; Martin, G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997, 36, 419-428.
2. Roth, B. L. Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry 1994, 6, 67-78.
3. Kroeze, W. K.; Roth, B. L. The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychiatry 1998, 44, 1128-1142.
4. Kroeze, W. K.; Sheffler, D. J.; Roth, B. L. G-protein-coupled receptors at a glance. J. Cell Sci. 2003, 116, 4867-4869.
5. Kroeze, W. K.; Kristiansen, K.; Roth, B. L. Molecular biology of serotonin receptors structure and function at the molecular level. Curr. Top. Med. Chem. 2002, 2, 507-528.
6. Nichols, D. E. Hallucinogens. Pharmacol. Ther. 2004, 101, 131-181.
7. Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.; Hufeisen, S. J.; Roth, B. L. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102, 2836-2841.
8. Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med. 2007, 356, 6-9.
9. Loke, Y. K.; Derry, S.; Pritchard-Copley, A. Appetite suppressants and valvular heart diseasesa systematic review. BMC Clin. Pharmacol. 2002, 2, 6.
10. Rocha, B. A.; Goulding, E. H.; O'Dell, L. E.; Mead, A. N.; Coufal, N. G.; Parsons, L. H.; Tecott, L. H. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J. Neurosci. 2002, 22, 10039-10045.
11. 2C serotonin receptors. Nature 1995, 374, 542-546.
12. 2C receptor knockout mouse. Physiol. BehaV. 2003, 78, 641-649.
13. Delgado, P. L.; Moreno, F. A. Hallucinogens, serotonin and obsessivecompulsive disorder. J. PsychoactiVe Drugs 1998, 30, 359-366.
14. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 1998, 286, 913-924.
15. Roth, B. L.; Shapiro, D. A. Insights into the structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development. Expert Opin. Ther. Targets 2001, 5, 685-695.
16. 2C receptor agonists: potential for the treatment of obesity. Mol. InterV. 2005, 5, 282-291.
17. Roth, B. L.; Lopez, E.; Patel, S.; Kroeze, W. K. The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches? Neuroscientist 2000, 6, 252-262.
18. 2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 59-67.
19. 2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. Eur. J. Pharmacol. 1997, 325, 9-12.
20. Cryan, J. F.; Lucki, I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 2000, 295, 1120-1126.
21. 2C receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. 2004, 488, 1-9.
22. 2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berlin) 2007, 192, 159-170.
23. Marquis, K. L.; Sabb, A. L.; Logue, S. F.; Brennan, J. A.; Piesla, M. J.; Comery, T. A.; Grauer, S. M.; Ashby, C. R., Jr.; Nguyen, H. Q.; Dawson, L. A.; Barrett, J. E.; Stack, G.; Meltzer, H. Y.; Harrison, B. L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR,10aR)- 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4] diazepino[6,7, 1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J. Pharmacol. Exp. Ther. 2007, 320, 486-496.
24. Berger, M.; Gray, J. A.; Roth, B. L. The Expanded Biology of Serotonin. Annu. ReV. Med. 2009, 60, 355-366.
25. 2C) receptor. Curr. Top. Med. Chem. 2006, 6, 1927-1970.
26. 2C) receptor agonists as potential antiobesity agents. J. Med. Chem. 2006, 49, 4023-4034.
27. 2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007, 52, 279-290.
28. Welmaker, G. S.; Nelson, J. A.; Sabalski, J. E.; Sabb, A. L.; Potoski, J. R.; Graziano, D.; Kagan, M.; Coupet, J.; Dunlop, J.; Mazandarani, H.; Rosenzweig-Lipson, S.; Sukoff, S.; Zhang, Y. Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1Hpyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1Hpyrazino[1,2-a]quinoxalines. Bioorg. Med. Chem. Lett. 2000, 10, 1991-1994.
29. 2C receptor. Bioorg. Med. Chem. Lett.2004, 14, 2603-2607.
30. 2C receptor agonist for the treatment of obesity. J. Med. Chem. 2008, 51, 305-313.
31. 2C receptor. J. Med. Chem. 2007, 50, 1365-1379.
32. 2C receptor: preclinical and clinical progression in multiple diseases. Curr. Opin. Drug. DiscoVery DeV. 2008, 11, 438-445.
33. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human 2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
34. Rasmussen, S. G.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R.; Sanishvili, R.; Fischetti, R. F.; Schertler, G. F.; Weis, W. I.; Kobilka, B. K. Crystal structure of the human 2 adrenergic G-protein-coupled receptor. Nature 2007, 450, 383-387.
35. Rosenbaum, D. M.; Cherezov, V.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Yao, X. J.; Weis, W. I.; Stevens, R. C.; Kobilka, B. K. GPCR engineering yields highresolution structural insights into 2-adrenergic receptor function. Science 2007, 318, 1266-1273.
36. Rohl, C. A.; Strauss, C. E.; Chivian, D.; Baker, D. Modeling structurally variable regions in homologous Proteins with rosetta. Proteins 2004, 55, 656-677.
37. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L., III. Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
38. Burger, A.; Walter, C. R., Jr.; Bennet, W. B.; Turnbull, L. B. Arylcycloalkylamines. Science 1950, 112, 306.
39. Burger, A.; Yost, W. L. Arylcycloalkylamines. I. 2- Phenylcyclopropylamine. J. Am. Chem. Soc. 1948, 70, 2198-2201.
40. Prestwick Drug Library; Prestwick Chemical: Illkirch, France, 2006; http://www.prestwickchemical.fr/ (accessed March 3, 2009).
41. Teotino, U. M.; Bella, D. D.; Gandini, A.; Benelli, G. Chemical and biological properties of some aminomethyl-2-phenylcyclopropane derivatives. Pharmacological comparison with tranylcypromine. J. Med. Chem. 1967, 10, 1091-1096.
42. Zirkle, C. L.; Kaiser, C.; Tedeschi, D. H.; Tedeschi, R. E.; Burger, A. 2-Substituted Cyclopropylamines. II. Effect of Structure Upon Monoamine Oxidase-Inhibitory Activity as Measured in Vivo by Potentiation of Tryptamine Convulsions. J. Med. Pharm. Chem. 1962, 5, 1265-1284.
43. Yoshida, S.; Meyer, O. G.; Rosen, T. C.; Haufe, G.; Ye, S.; Sloan, M. J.; Kirk, K. L. Fluorinated phenylcyclopropylamines. 1. Synthesis and effect of fluorine substitution at the cyclopropane ring on inhibition of microbial tyramine oxidase. J. Med. Chem. 2004, 47, 1796-1806.
44. Krishnamurthy, S. A highly efficient and general N-monomethylation of functionalized primary amines via formylationsborane:methyl sulfide reduction. Tetrahedron Lett. 1982, 23, 3315-3318.
45. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R?ánalogues: acquisition of potent δ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
46. Arvidsson, L. E.; Johansson, A. M.; Hacksell, U.; Nilsson, J. L.; Svensson, K.; Hjorth, S.; Magnusson, T.; Carlsson, A.; Lindberg, P.; Andersson, B. N,N-Dialkylated monophenolic trans-2-phenylcyclopropylamines: novel central 5-hydroxytryptamine receptor agonists. J. Med. Chem. 1988, 31, 92-99.
47. Kawamoto, H.; Ozaki, S.; Itoh, Y.; Miyaji, M.; Arai, S.; Nakashima, H.; Kato, T.; Ohta, H.; Iwasawa, Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1- cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl- 1,3-dihydro-2H- benzimidazol-2-one (J-113397). J. Med. Chem. 1999, 42, 5061-5063.
48. Chandrasekhar, S.; Reddy, C. R.; Ahmed, M. A single step reductive amination of carbonyl compounds with polymethylhydrosiloxane- Ti((OPr)-Pr-i)(4). Synlett 2000, 1655-1657.
49. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. ReV. 1995, 95, 2457-2483.
50. DeVasher, R. B.; Moore, L. R.; Shaughnessy, K. H. Aqueous-phase, palladium-catalyzed cross-coupling of aryl bromides under mild conditions, using water-soluble, sterically demanding alkylphosphines. J. Org. Chem. 2004, 69, 7919-7927.
51. Overberger, C. G.; Shimokawa, Y. Synthesis and Optical Properties of Asymmetric Polyamides Derived from Optically Active Cyclic Dicarboxylic Acids. Macromolecules 1971, 4, 718-725.
52. Zhang, X.; Hodgetts, K.; Rachwal, S.; Zhao, H.; Wasley, J. W.; Craven, K.; Brodbeck, R.; Kieltyka, A.; Hoffman, D.; Bacolod, M. D.; Girard, B.; Tran, J.; Thurkauf, A. trans-1-[(2-Phenylcyclopropyl) methyl]-4-arylpiperazines: mixed dopamine D2/D4 receptor antagonists as potential antipsychotic agents. J. Med. Chem. 2000, 43, 3923-3932.
53. Jensen, N. H.; Rodriguiz, R. M.; Caron, M. G.; Wetsel, W. C.; Rothman, R. B.; Roth, B. L. N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. Neuropsychopharmacology 2007, 33, 2303-2312.
54. 2Creceptors. Synapse 2000, 35, 144-150.
55. 2Creceptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug ReV. 2006, 12, 167-177.